证券代码：300078 证券简称：思创医惠 公告编号：2025-125 思创医惠科技股份有限公司 第六届董事会第十六次会议决议公告 表决结果：8 票同意，0 票反对，0 票弃权。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会第十六次会 议于 2025 年 12 月 29 日在浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼 会议室以现场表决和通讯表决相结合的方式召开。会议通知于 2025 年 12 月 26 日通过电子邮件、电话方式送达各位董事。本次会议应出席董事 8 人，实际出席 董事 8 人。会议由董事长魏乃绪先生召集并主持，公司高级管理人员列席了会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规和 《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于拟变更公司名称、证券简称暨修订<公司章程>的议案》 为更加全面体现公司核心业务和产业布局，传递公司的战略发展方向，董事 会同意本次对公司名称、证券简称进行变更。公司中文名称拟变更 ...

北京天元（杭州）律师事务所 关于思创医惠科技股份有限公司 2025 年第七次临时股东会的法律意见 的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相 应法律责任。 本所及经办律师同意将本法律意见作为本次股东会公告的法定文件，随同其 他公告文件一并提交深圳证券交易所（以下简称"深交所"）予以公告，并依法对 出具的法律意见承担责任。 京天股字（2025）第 797 号 致：思创医惠科技股份有限公司 思创医惠科技股份有限公司（以下简称"公司"）2025 年第七次临时股东会（以 下简称"本次股东会"）采取现场表决与网络投票相结合的方式，现场会议于 2025 年 12 月 29 日（星期一）下午 15:00 在公司会议室（浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室）召开。北京天元（杭州）律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东会现场会议，并根据《中华人民 共和国公司法》、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股东会规则》（以下简称"《股东会规则》"）以及《思创医惠科技股份有限 公司章程》（以下简称"《公司章程》"）等有关规 ...

2025 年第七次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300078 证券简称：思创医惠 公告编号：2025-129 思创医惠科技股份有限公司 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 12 月 29 日（星期一）15:00 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 29 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 29 日 9:15 至 15:00 期间的任意时间。 3、现场会议召开地点：浙江省杭州市滨江区月明路 567 号"医惠中心"23 楼会议室 4、会议召开方式：本次股东会采取现场投票表决和网络投票表决相结合的 方式 5、会议召集人：公司董事会 6、会议主持人：公司董事长魏乃绪先生 7、会议召开的合法、合规性：本次股东会的召集、召开及表决程序符合《中 ...

"严重失实，涉及造谣" 投资"九死一生"的科创企业，国资基金如何在耐心资本与投资回报之间找到平衡？ 12月26日下午，华中科技大学同济医院器官移植研究所前副所长、浙江仝干医疗科技股份有限公司（下称"仝干医科"）创 始人及董事长周平在社交媒体上发布一封公开控诉信，直指科技创业者耗尽12年心血打造的、全球唯一获批临床收费的生 物人工肝企业，正被浙江省温州市苍南县国资违规强夺，导致仝干医科三大基地生产停滞，数千万建设资金打水漂，创始 大股东被逼出局。 对此，苍南公共事业投资集团董事长叶青健26日晚间在接受第一财经记者采访时称，周平微博我方已关注到，此微博（内 容）严重失实，涉及造谣。 孔雀东南飞"折翅" 公开资料显示，周平从事器官移植及普通外科临床有30多年。早在1997年，周平就在美国参与生物人工肝的早期研发， 2006年起与日本冈山大学医院联合研发永生化人源肝细胞生物人工肝，2010年自主研发了HepAssis2生物人工肝系统。 2013年，周平在武汉成立仝干医科，开始了HepAssis2生物人工肝系统的产业化。从2015年开始，仝干医科先后获得四轮融 资。 2023年7月，苍南县政府及国资11人团队赴武汉考察 ...

Group 1 - The core viewpoint of the news is that Sichuang Medical's stock performance and financial metrics indicate a mixed outlook, with notable fluctuations in financing activities and shareholder statistics [1][2]. Group 2 - On December 19, Sichuang Medical's stock fell by 1.14%, with a trading volume of 425 million yuan. The financing buy-in amount for the day was 18.70 million yuan, while the financing repayment was 16.07 million yuan, resulting in a net financing buy of 2.63 million yuan. The total financing and securities balance reached 156 million yuan [1]. - The financing balance of Sichuang Medical is 156 million yuan, accounting for 3.21% of the circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high position [1]. - On the same day, Sichuang Medical repaid 1,400 shares in securities lending and sold 13,200 shares, with a selling amount of 57,400 yuan. The remaining securities lending volume was 66,000 shares, with a balance of 287,100 yuan, exceeding the 90th percentile level over the past year, indicating a high position [1]. Group 3 - As of September 30, the number of shareholders for Sichuang Medical was 58,400, a decrease of 11.34% from the previous period. The average circulating shares per person increased by 12.79% to 19,077 shares [2]. - For the period from January to September 2025, Sichuang Medical achieved an operating income of 604 million yuan, representing a year-on-year growth of 6.95%. However, the net profit attributable to the parent company was -4.76 million yuan, showing a year-on-year increase of 98.32% in losses [2]. Group 4 - Since its A-share listing, Sichuang Medical has distributed a total of 532 million yuan in dividends. However, there have been no dividend distributions in the past three years [3].

Group 1 - The core viewpoint of the article highlights a new trend in A-share control rights changes, characterized by "small proportion transfer + voting rights arrangement," with five companies announcing such changes since November [1] - The companies involved include Hangzhou Genghao, which acquired control of Chuangye Huikang through a 6.23% equity transfer and a 10.06% voting rights delegation, and Xutong Investment, which took control of Hualan Group via a 5.79% equity transfer and a 13.71% voting rights delegation [1] - This low-cost control model allows acquirers to gain control without holding a high percentage of shares, driven by original controlling shareholders' low shareholding ratios and restrictions on large transfers due to specific conditions [1] Group 2 - The trend is referred to as "small share operation" within the industry, where the acquirer can control the listed company without needing a significant shareholding [1] - Original controlling shareholders aim to maximize profits by selling only a portion of their shares while retaining some, anticipating that the new controlling party will bring in quality industry resources and subsequently increase the stock price for better returns on remaining shares [1]

Core Viewpoint - The recent trend of "small proportion transfer + voting rights arrangement" in A-share control changes has gained momentum, allowing acquirers to gain control of companies at a low cost, exemplified by ST Zhiyun's acquisition for 87 million yuan, despite its market value nearing 2 billion yuan [1][2] Group 1: Transaction Characteristics - Five companies have announced control changes through "small proportion transfer + voting rights arrangement" since November, showcasing a high degree of homogeneity in transaction structure, pricing mechanisms, and the nature of the parties involved [2][4] - The acquisition structures typically involve share transfers between 5% and 10%, which meet regulatory requirements while avoiding triggering mandatory takeover bids, thus facilitating low-cost control [4][7] - The pricing mechanism predominantly features discounted transactions, with ST Zhiyun and others selling shares below the market price prior to announcements, reducing financial pressure on acquirers [5][6] Group 2: Financial and Operational Context - The companies involved generally have small to medium market capitalizations, with four out of five having market values between 2 billion and 5 billion yuan, and they face performance pressures, indicating a low risk of delisting [8][9] - Financial data reveals that most companies are underperforming, with four reporting losses in the first three quarters of the year, while only one, Hualan Group, has turned a profit [9][10] Group 3: Stakeholder Dynamics - The acquirers are predominantly private entities, which allows for quicker decision-making processes compared to state-owned enterprises, enhancing transaction efficiency [7][11] - The original shareholders often retain a portion of their stakes, creating a shared interest in the company's future performance, which aligns the interests of both parties [17] Group 4: Regulatory and Market Environment - The emergence of this acquisition model is supported by regulatory changes that encourage market-oriented mergers and acquisitions, particularly for private capital [18][19] - Recent regulatory proposals have raised concerns about the compliance of voting rights arrangements, which could impact future control transactions if enacted [22]

北京商报讯（记者 丁宁）12月19日晚间，深交所官网显示，深交所向思创医惠（300078）下发监管 函。 据悉，2017年6月，章笠中作为公司时任董事长兼总经理，以公司子公司医惠科技有限公司（以下简 称"医惠科技"）名义为其个人7600万元借款提供担保。章笠中未将上述担保事项告知公司，导致公司未 履行相应的审议程序，未及时披露有关事项。 此外，2024年11月，因章笠中违约，债权人提起诉讼并向法院申请财产保全，医惠科技的募集资金专项 账户被冻结资金5766.25万元。2025 年5月，章笠中履行还款义务后，法院裁定解除对医惠科技5766.25 万元银行存款的冻结。 深交所表示，思创医惠未严格管控上市公司及子公司公章，未能有效防范违规担保事项发生，公司印章 管理内部控制存在缺陷。公司的上述行为违反了《创业板股票上市规则》第1.4条和《创业板上市公司 规范运作指引》第1.4条、第8.1.1条、第8.1.7条的规定。要求公司董事会充分重视上述问题，吸取教 训，及时整改，杜绝上述问题的再次发生。 同时，鉴于上述违规事实及情节，深交所对思创医惠时任董事长兼总经理章笠中给予通报批评的处分。 ...

Core Viewpoint - The transaction of control rights in Sichuang Medical Technology involves the general manager Wei Naixu achieving MBO through a "share transfer + voting rights" model. The company previously attempted to sell to state-owned assets but was terminated due to non-compliance with relevant state-owned asset regulations. Notably, state-owned assets are indirectly involved in the MBO process [1][6][8]. Group 1: Control Rights Transactions - As of December 15, over 170 listed companies have undergone changes in actual controllers, with methods including agreement transfers, voting rights entrustment, and judicial auctions [1]. - The "small shareholding + voting rights entrustment" model is frequently used in control rights transactions, as seen in companies like Guao Technology and ST Zhiyun [2][14]. Group 2: Advantages of the New Transaction Model - The "small shareholding + voting rights entrustment" model allows acquirers to achieve control at a minimal cost, providing significant leverage and reducing premium payments [4][16]. - This model can facilitate control transfer for sellers facing restrictions on share freezing or reduction, enhancing transaction efficiency by avoiding mandatory tender offer obligations [4][16]. Group 3: Case Study of Sichuang Medical Technology - In the control rights transaction, Wei Naixu acquired 5.61% of shares through a transfer agreement priced at 2.872 yuan per share, totaling 180 million yuan [6][17]. - After the transaction, Wei Naixu indirectly held 7.47% of shares and controlled 13.18% of voting rights, making him the actual controller of Sichuang Medical Technology [7][18]. Group 4: Historical Issues and Risks - Sichuang Medical Technology has faced regulatory penalties for financial fraud, including inflated revenues and profits in previous years, leading to significant fines and market bans for executives [11][22]. - The company is currently under investigation for fraudulent issuance, with ongoing legal scrutiny affecting its stock performance [12][23].

登录新浪财经APP 搜索【信披】查看更多考评等级 出品：新浪财经上市公司研究院 文/夏虫工作室 核心观点：冯彬与邓晖通过慧达富能采取"协议转让+表决委托"拿下ST智云（维权）控股权。值得注意 的是，上市公司因财务造假被ST，叠加其基本面羸弱，未来又是否可能存在保壳压力？ 随着二级市场行情火爆，A股上市公司控制权交易也显得异常活跃。据wind统计，截止12月15日，出现 实控人变更的上市公司数量超170家，从变更方式看分别包括协议转让、表决权委托、无偿划转、司法 拍卖等几种形式。 | A 正存代到 | 让东名材 | 止存类 | A | 事件大学 | 重量家。 | 发生日期Y | 事件损失 | | 拔露日期。 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 300551. SZ | 古盈科技 | 股票 | | 公司资料变 | 实际控制人 | 2025-12-12 | 实际控制 | N | 2025-12-15 | | 603179. SH | 新泉股份 | 股票 | | 公司资料变 | 实际控制人 | 2025-12-12 | 实 ...